Boston Scientific Corp

Boston Scientific announces conference call discussing first quarter 2026 results

CHAMPION-AF study of the WATCHMAN FLX™ Left Atrial Appendage Closure Device as a first-line therapy for stroke risk reduction meets all primary and secondary safety and efficacy endpoints

HI-PEITHO trial demonstrates Boston Scientific EKOS™ Endovascular System is superior to standard of care for treatment of acute pulmonary embolism

Boston Scientific to host investor event at the 75th Annual Scientific Session of the American College of Cardiology

Boston Scientific elects Cathy Smith and Christophe Weber to Board of Directors